サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1375934

泌尿器科におけるボツリヌス毒素の市場規模、シェア、動向分析レポート：用途別、最終用途別、地域別、セグメント別予測、2023～2030年

Botulinum Toxin In Urology Market Size, Share & Trends Analysis Report By Application (Overactive Bladder, Neurogenic Detrusor Overactivity), By End-use (Hospitals, Urology Clinics), By Region, And Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 110 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
泌尿器科におけるボツリヌス毒素の市場規模、シェア、動向分析レポート：用途別、最終用途別、地域別、セグメント別予測、2023～2030年
出版日: 2023年10月16日
発行: Grand View Research
ページ情報: 英文 110 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

泌尿器科におけるボツリヌス毒素市場の成長と動向：

Grand View Research社の最新レポートによると、泌尿器科におけるボツリヌス毒素の世界市場規模は2030年までに14億5,000万米ドルに達すると予測されています。

市場は2023年から2030年にかけてCAGR 6.0％で成長すると予測されています。ボツリヌス毒素の需要は、神経因性膀胱の有病率の上昇、排尿状態の問題や尿失禁に関連する高齢者人口の増加により拡大しています。例えば、米国国勢調査局2020によると、2023年5月には、米国の人口の16.8％にあたる約5,580万人が高齢者に分類されています。その結果、高齢者人口の増加が泌尿器疾患問題の増加につながり、市場成長にさらにつながっています。

また、2023年5月にオーストラリア大陸財団（Continence Foundation of Australia）によると、オーストラリアでは尿失禁が女性の約38％、男性の約10％に影響を与えています。したがって、尿失禁の有病率の増加が市場の成長を押し上げました。尿失禁の原因は、便秘、骨盤底障害、脳卒中、特定の薬の副作用などです。

しかし、泌尿器科におけるボツリヌス菌の治療アプローチを探求するために、政府や民間組織による研究開発への投資が増加していることが、市場に新たな機会を生み出しています。例えば、2022年7月、AbbVie Inc.とAllergan PLCは、ニューオーリンズで開催されたTOXINS 2022 Conferenceで、7つの演壇発表を含む30以上の演題を発表しました。そこでは、オナボツリヌムトキシンAの前臨床研究、臨床研究、実際の使用データが強調されました。このように、様々な機関による資金提供の増加が市場の成長を後押ししています。

泌尿器科におけるボツリヌス毒素市場レポートハイライト

  • 用途別では、過活動膀胱分野が2022年に67.14%の最大市場シェアを占め、予測期間中に最も速いCAGRを記録すると予測されています。腹部外傷、過度のアルコール摂取、神経損傷などの要因が過活動膀胱の発生率を高め、このセグメントの成長をさらに高めています。
  • 最終用途別では、病院セグメントが2022年に73.74%の最大市場シェアを占めました。新興国市場における病院数の増加と技術の進歩が、このセグメントの市場成長を促進しています。
  • 北米地域は、2022年に37.41%の最大シェアを占め、市場をリードする地域に浮上しました。同地域の強固な医療インフラ、熟練した医療専門家、高度な医療施設が同地域の市場成長に寄与しています。
  • アジア太平洋は、慢性疾患と糖尿病の有病率の増加により、予測期間中に最速のCAGR 7.3%を記録すると予測されています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場変数、動向、および範囲

  • 市場系統の展望
  • 市場動向と展望
  • 市場力学
  • 市場抑制要因分析
  • 事業環境分析
  • 経済効果分析

第4章 アプリケーションビジネス分析

  • 泌尿器科市場におけるボツリヌス毒素、用途別：重要なポイント
  • 泌尿器科市場におけるボツリヌス毒素：用途の動きと市場シェア分析、2022年と2030年
  • 過活動膀胱
    • 世界の過活動膀胱市場推計・予測、2018～2030年
  • 神経因性排尿筋過活動
    • 世界の神経因性排尿筋過活動市場推計・予測、2018～2030年

第5章 最終用途ビジネス分析

  • 泌尿器科におけるボツリヌス毒素市場、最終用途別：重要なポイント
  • 泌尿器科におけるボツリヌス毒素市場：最終用途の動向と市場シェア分析、2022年と2030年
  • 病院
  • 泌尿器科クリニック

第6章 地域ビジネス分析

  • 地域市場のスナップショット
  • 北米
    • 北米の泌尿器科におけるボツリヌス毒素市場、2018～2030年
    • 米国
    • カナダ
  • 欧州
    • 欧州の泌尿器科におけるボツリヌス毒素市場、2018～2030年
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋
    • アジア太平洋の泌尿器科におけるボツリヌス毒素市場、2018～2030年
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • ラテンアメリカの泌尿器科におけるボツリヌス毒素市場、2018～2030年
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • 中東・アフリカの泌尿器科におけるボツリヌス毒素市場、2018～2030年
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 企業の分類
  • 戦略マッピング
  • 企業プロファイル・一覧表
    • AbbVie Inc.
    • Merz Pharma
    • Ipsen Pharma
    • GALDERMA
    • Allergan PLC
    • Sun Pharmaceutical Industries Ltd.
    • Biovencer Healthcare Pvt Ltd
図表

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 Global Botulinum Toxin In Urology Market, by application, 2018 - 2030 (USD Million)
  • Table 3 Global Botulinum Toxin In Urology Market, by end-use, 2018 - 2030 (USD Million)
  • Table 4 Global Botulinum Toxin In Urology Market, by region, 2018 - 2030 (USD Million)
  • Table 5 North America Botulinum Toxin In Urology Market, by country, 2018 - 2030 (USD Million)
  • Table 6 North America Botulinum Toxin In Urology Market, by application, 2018 - 2030 (USD Million)
  • Table 7 North America Botulinum Toxin In Urology Market, by End-use, 2018 - 2030 (USD Million)
  • Table 8 U.S. Botulinum Toxin In Urology Market, by application, 2018 - 2030 (USD Million)
  • Table 9 U.S. Botulinum Toxin In Urology Market, by End-use, 2018 - 2030 (USD Million)
  • Table 10 Canada Botulinum Toxin In Urology Market, by application, 2018 - 2030 (USD Million)
  • Table 11 Canada Botulinum Toxin In Urology Market, by End-use, 2018 - 2030 (USD Million)
  • Table 12 Europe Botulinum Toxin In Urology Market, by country, 2018 - 2030 (USD Million)
  • Table 13 Europe Botulinum Toxin In Urology Market, by application, 2018 - 2030 (USD Million)
  • Table 14 Europe Botulinum Toxin In Urology Market, by end-use, 2018 - 2030 (USD Million)
  • Table 15 Germany Botulinum Toxin In Urology Market, by application, 2018 - 2030 (USD Million)
  • Table 16 Germany Botulinum Toxin In Urology Market, by end-use, 2018 - 2030 (USD Million)
  • Table 17 UK Botulinum Toxin In Urology Market, by application, 2018 - 2030 (USD Million)
  • Table 18 UK Botulinum Toxin In Urology Market, by end-use, 2018 - 2030 (USD Million)
  • Table 19 France Botulinum Toxin In Urology Market, by application, 2018 - 2030 (USD Million)
  • Table 20 France Botulinum Toxin In Urology Market, by end-use, 2018 - 2030 (USD Million)
  • Table 21 Italy Botulinum Toxin In Urology Market, by application, 2018 - 2030 (USD Million)
  • Table 22 Italy Botulinum Toxin In Urology Market, by end-use, 2018 - 2030 (USD Million)
  • Table 23 Spain Botulinum Toxin In Urology Market, by application, 2018 - 2030 (USD Million)
  • Table 24 Spain Botulinum Toxin In Urology Market, by end-use, 2018 - 2030 (USD Million)
  • Table 25 Denmark Botulinum Toxin In Urology Market, by application, 2018 - 2030 (USD Million)
  • Table 26 Denmark Botulinum Toxin In Urology Market, by end-use, 2018 - 2030 (USD Million)
  • Table 27 Sweden Botulinum Toxin In Urology Market, by application, 2018 - 2030 (USD Million)
  • Table 28 Sweden Botulinum Toxin In Urology Market, by end-use, 2018 - 2030 (USD Million)
  • Table 29 Norway Botulinum Toxin In Urology Market, by application, 2018 - 2030 (USD Million)
  • Table 30 Norway Botulinum Toxin In Urology Market, by end-use, 2018 - 2030 (USD Million)
  • Table 31 Asia Pacific Botulinum Toxin In Urology Market, by country, 2018 - 2030 (USD Million)
  • Table 32 Asia Pacific Botulinum Toxin In Urology Market, by application, 2018 - 2030 (USD Million)
  • Table 33 Asia Pacific Botulinum Toxin In Urology Market, by end-use, 2018 - 2030 (USD Million)
  • Table 34 China Botulinum Toxin In Urology Market, by application, 2018 - 2030 (USD Million)
  • Table 35 China Botulinum Toxin In Urology Market, by end-use, 2018 - 2030 (USD Million)
  • Table 36 Japan Botulinum Toxin In Urology Market, by application, 2018 - 2030 (USD Million)
  • Table 37 Japan Botulinum Toxin In Urology Market, by end-use, 2018 - 2030 (USD Million)
  • Table 38 India Botulinum Toxin In Urology Market, by application, 2018 - 2030 (USD Million)
  • Table 39 India Botulinum Toxin In Urology Market, by end-use, 2018 - 2030 (USD Million)
  • Table 40 South Korea Botulinum Toxin In Urology Market, by application, 2018 - 2030 (USD Million)
  • Table 41 South Korea Botulinum Toxin In Urology Market, by end-use, 2018 - 2030 (USD Million)
  • Table 42 Australia Botulinum Toxin In Urology Market, by application, 2018 - 2030 (USD Million)
  • Table 43 Australia Botulinum Toxin In Urology Market, by end-use, 2018 - 2030 (USD Million)
  • Table 44 Thailand Botulinum Toxin In Urology Market, by application, 2018 - 2030 (USD Million)
  • Table 45 Thailand Botulinum Toxin In Urology Market, by end-use, 2018 - 2030 (USD Million)
  • Table 46 Latin America Botulinum Toxin In Urology Market, by country, 2018 - 2030 (USD Million)
  • Table 47 Latin America Botulinum Toxin In Urology Market, by application, 2018 - 2030 (USD Million)
  • Table 48 Latin America Botulinum Toxin In Urology Market, by end-use, 2018 - 2030 (USD Million)
  • Table 49 Brazil Botulinum Toxin In Urology Market, by application, 2018 - 2030 (USD Million)
  • Table 50 Brazil Botulinum Toxin In Urology Market, by end-use, 2018 - 2030 (USD Million)
  • Table 51 Mexico Botulinum Toxin In Urology Market, by application, 2018 - 2030 (USD Million)
  • Table 52 Mexico Botulinum Toxin In Urology Market, by end-use, 2018 - 2030 (USD Million)
  • Table 53 Argentina Botulinum Toxin In Urology Market, by application, 2018 - 2030 (USD Million)
  • Table 54 Argentina Botulinum Toxin In Urology Market, by end-use, 2018 - 2030 (USD Million)
  • Table 55 Middle East & Africa Botulinum Toxin In Urology Market, by application, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa Botulinum Toxin In Urology Market, by end-use, 2018 - 2030 (USD Million)
  • Table 57 South Africa Botulinum Toxin In Urology Market, by application, 2018 - 2030 (USD Million)
  • Table 58 South Africa Botulinum Toxin In Urology Market, by end-use, 2018 - 2030 (USD Million)
  • Table 59 Saudi Arabia Botulinum Toxin In Urology Market, by application, 2018 - 2030 (USD Million)
  • Table 60 Saudi Arabia Botulinum Toxin In Urology Market, by end-use, 2018 - 2030 (USD Million)
  • Table 61 UAE Botulinum Toxin In Urology Market, by application, 2018 - 2030 (USD Million)
  • Table 62 UAE Botulinum Toxin In Urology Market, by end-use, 2018 - 2030 (USD Million)
  • Table 63 Kuwait Botulinum Toxin In Urology Market, by application, 2018 - 2030 (USD Million)
  • Table 64 Kuwait Botulinum Toxin In Urology Market, by end-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 Botulinum Toxin In Urology Market Segmentation
  • Fig. 8 Market snapshot, 2022
  • Fig. 9 Market Trends & outlook
  • Fig. 10 Market driver relevance analysis (Current & future impact)
  • Fig. 11 Market restraint relevance analysis (Current & future impact)
  • Fig. 12 Swot analysis, by factor (political & legal, economic and technological)
  • Fig. 13 Porter's Five Forces analysis
  • Fig. 14 Global Botulinum Toxin In Urology Market: Application Outlook Key Takeaways
  • Fig. 15 Global Botulinum Toxin In Urology Market: Application Movement Analysis
  • Fig. 16 Global Overactive Bladder Market, 2018 - 2030 (USD Million)
  • Fig. 17 Global Neurogenic Detrusor Overactivity Market, 2018 - 2030 (USD Million)
  • Fig. 18 Global Botulinum Toxin In Urology Market: End-use Outlook Key Takeaways
  • Fig. 19 Global Botulinum Toxin In Urology Market: End-use Movement Analysis
  • Fig. 20 Global Hospitals Market, 2018 - 2030 (USD Million)
  • Fig. 21 Global Urology Clinics Market, 2018 - 2030 (USD Million)
  • Fig. 22 Regional Marketplace: Key Takeaways
  • Fig. 23 Regional Outlook, 2022 & 2030
  • Fig. 24 Global Botulinum Toxin In Urology Market: Region Movement Analysis
  • Fig. 25 North America Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
  • Fig. 26 U.S. Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
  • Fig. 27 Canada Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
  • Fig. 28 Europe Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
  • Fig. 29 Germany Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
  • Fig. 30 UK Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
  • Fig. 31 France Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
  • Fig. 32 Italy Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
  • Fig. 33 Spain Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
  • Fig. 34 Spain Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
  • Fig. 35 Denmark Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
  • Fig. 36 Sweden Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
  • Fig. 37 Norway Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
  • Fig. 38 Asia Pacific Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
  • Fig. 39 Japan Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
  • Fig. 40 China Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
  • Fig. 41 India Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
  • Fig. 42 Australia Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
  • Fig. 43 South Korea Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
  • Fig. 44 Thailand Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
  • Fig. 45 Latin America Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
  • Fig. 46 Brazil Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
  • Fig. 47 Mexico Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
  • Fig. 48 Argentina Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
  • Fig. 49 Middle East and Africa Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
  • Fig. 50 South Africa Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
  • Fig. 51 Saudi Arabia Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
  • Fig. 52 UAE Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
  • Fig. 53 Kuwait Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
目次
Product Code: GVR-4-68040-138-5

Botulinum Toxin In Urology Market Growth & Trends:

The global botulinum toxin in urology market size is anticipated to reach USD 1.45 billion by 2030, according to a new report by Grand View Research, Inc.. The market is projected to grow at a CAGR of 6.0% from 2023 to 2030. The demand for botulinum toxin is growing due to a rise in the prevalence of neurogenic bladder, rising geriatric population associated with urinary condition problems and urinary incontinence. For instance, in May 2023, according to the U.S. Census Bureau 2020, around 55.8 million or 16.8% of the population in the U.S. has been classified as older. As a result, the rising geriatric population has led to an increase in urinary condition problems, further leading to market growth.

In addition, in May 2023, according to the Continence Foundation of Australia, urinary incontinence affects about 38% of women and 10% of men in Australia. Thus, the increase in the prevalence of urinary incontinence raised the growth of the market. Urinary incontinence is caused due to constipation, pelvic floor disorders, stroke, and side effects of certain medications.

However, rising investment in R&D by government and private organizations to explore the therapeutic approach of botulinum in the urology sector creates new opportunities for the market. For instance, in July 2022, AbbVie Inc. and Allergan PLC presented more than 30 abstracts, including seven podium presentations at the TOXINS 2022 Conference in New Orleans. It highlighted preclinical research, clinical studies, and real-world utilization data of onabotulinumtoxinA. Thus, increased funding by various institutions boosts market growth.

Botulinum Toxin In Urology Market Report Highlights:

  • In terms of application, the overactive bladder segment held the largest market share of 67.14% in 2022 and it is anticipated to register the fastest CAGR over the forecast period. Factors such as abdominal trauma, excessive alcohol consumption, and nerve damage increase the incidence of overactive bladder, further increasing the segment's growth
  • Based on end-use, the hospitals segment held the largest market share of 73.74% in 2022. The growing number of hospitals in developing nations and technological advancements are fueling the market growth of this segment
  • North America region emerged as the leading market region in 2022, holding the largest share of 37.41%. The region's robust healthcare infrastructure, skilled healthcare professionals, and advanced medical facilities contribute to the market growth in the region.
  • The Asia Pacific region is anticipated to register the fastest CAGR of 7.3% over the forecast period owing to the increased prevalence of chronic diseases and diabetes

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's Internal Database
    • 1.3.3. Secondary Sources & Third-Party Perspectives
    • 1.3.4. Primary Research
    • 1.3.5. Details of Primary Research
  • 1.4. Information Analysis
    • 1.4.1. Data Analysis Models
  • 1.5. Market Formulation & Data Visualization
    • 1.5.1. Commodity Flow Analysis
      • 1.5.1.1. Approach 1: Commodity flow approach
  • 1.6. Data Validation & Publishing
  • 1.7. Global Market: CAGR Calculation
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Restraint Analysis
  • 3.5. Business Environment Analysis
    • 3.5.1. SWOT Analysis; By Factor (Political & Legal, Economic and Technological)
    • 3.5.2. Porter's Five Forces Analysis
  • 3.6. Economic Impact Analysis

Chapter 4. Application Business Analysis

  • 4.1. Botulinum Toxin In Urology Market, By Application: Key Takeaways
  • 4.2. Botulinum Toxin In Urology Market: Application Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Overactive Bladder
    • 4.3.1. Global Overactive Bladder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Neurogenic Detrusor Overactivity
    • 4.4.1. Global Neurogenic Detrusor Overactivity Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. End-Use Business Analysis

  • 5.1. Botulinum Toxin In Urology Market, By End-use: Key Takeaways
  • 5.2. Botulinum Toxin In Urology Market: End-use Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Hospitals
    • 5.3.1. Global Hospitals Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Urology Clinics
    • 5.4.1. Global Urology Clinics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Regional Business Analysis

  • 6.1. Regional Market Snapshot
  • 6.2. North America
    • 6.2.1. North America Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
    • 6.2.2. U.S.
      • 6.2.2.1. U.S. Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
    • 6.2.3. Canada
      • 6.2.3.1. Canada Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
  • 6.3. Europe
    • 6.3.1. Europe Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
    • 6.3.2. Germany
      • 6.3.2.1. Germany Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
    • 6.3.3. UK
      • 6.3.3.1. UK Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
    • 6.3.4. France
      • 6.3.4.1. France Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
    • 6.3.5. Italy
      • 6.3.5.1. Italy Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
    • 6.3.6. Spain
      • 6.3.6.1. Spain Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
    • 6.3.7. Denmark
      • 6.3.7.1. Denmark Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
    • 6.3.8. Sweden
      • 6.3.8.1. Sweden Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
    • 6.3.9. Norway
      • 6.3.9.1. Norway Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
    • 6.4.2. Japan
      • 6.4.2.1. Japan Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
    • 6.4.3. China
      • 6.4.3.1. China Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
    • 6.4.4. India
      • 6.4.4.1. India Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
    • 6.4.5. South Korea
      • 6.4.5.1. South Korea Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
    • 6.4.6. Australia
      • 6.4.6.1. Australia Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
    • 6.4.7. Thailand
      • 6.4.7.1. Thailand Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
  • 6.5. Latin America
    • 6.5.1. Latin America Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
    • 6.5.2. Brazil
      • 6.5.2.1. Brazil Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
    • 6.5.3. Mexico
      • 6.5.3.1. Mexico Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
    • 6.5.4. Argentina
      • 6.5.4.1. Argentina Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
  • 6.6. MEA
    • 6.6.1. MEA Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
    • 6.6.2. South Africa
      • 6.6.2.1. South Africa Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
    • 6.6.3. Saudi Arabia
      • 6.6.3.1. Saudi Arabia Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
    • 6.6.4. UAE
      • 6.6.4.1. UAE Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)
    • 6.6.5. Kuwait
      • 6.6.5.1. Kuwait Botulinum Toxin In Urology Market, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
  • 7.2. Strategy Mapping
  • 7.3. Company Profiles/Listing
    • 7.3.1. AbbVie Inc.
      • 7.3.1.1. Overview
      • 7.3.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.3.1.3. Product Benchmarking
      • 7.3.1.4. Strategic Initiatives
    • 7.3.2. Merz Pharma
      • 7.3.2.1. Overview
      • 7.3.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.3.2.3. Product Benchmarking
      • 7.3.2.4. Strategic Initiatives
    • 7.3.3. Ipsen Pharma
      • 7.3.3.1. Overview
      • 7.3.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.3.3.3. Product Benchmarking
      • 7.3.3.4. Strategic Initiatives
    • 7.3.4. GALDERMA
      • 7.3.4.1. Overview
      • 7.3.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.3.4.3. Product Benchmarking
      • 7.3.4.4. Strategic Initiatives
    • 7.3.5. Allergan PLC
      • 7.3.5.1. Overview
      • 7.3.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.3.5.3. Product Benchmarking
      • 7.3.5.4. Strategic Initiatives
    • 7.3.6. Sun Pharmaceutical Industries Ltd.
      • 7.3.6.1. Overview
      • 7.3.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.3.6.3. Product Benchmarking
      • 7.3.6.4. Strategic Initiatives
    • 7.3.7. Biovencer Healthcare Pvt Ltd
      • 7.3.7.1. Overview
      • 7.3.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.3.7.3. Product Benchmarking
      • 7.3.7.4. Strategic Initiatives